Difference in the pharmacokinetics and hepatic metabolism of antidiabetic drugs in Zucker diabetic fatty and sprague-dawley rats

Drug Metabolism and Disposition

Volumn 44, Issue 8, 2016, Pages 1184-1192

  Zhou, Xin ^a   Rougée, Luc R A ^a   Bedwell, David W ^a   Cramer, Jeff W ^a   Mohutsky, Michael A ^a   Calvert, Nathan A ^a   Moulton, Richard D ^a   Cassidy, Kenneth C ^a   Yumibe, Nathan P ^a   Adams, Lisa A ^a   Ruterbories, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; CYTOCHROME P450 2C; GLIBENCLAMIDE; GLUCURONOSYLTRANSFERASE; INSULIN; METFORMIN; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; CYTOCHROME P-450 CYP2C SUBFAMILY; CYTOCHROME P450; CYTOCHROME P450 3A; SULFOTRANSFERASE;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RAT STRAIN; SPRAGUE DAWLEY RAT; URINARY EXCRETION; ANIMAL; BIOTRANSFORMATION; BLOOD; COMPARATIVE STUDY; ENZYME SPECIFICITY; ENZYMOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER CELL; METABOLISM; SPECIES DIFFERENCE; ZUCKER RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIOTRANSFORMATION; CANAGLIFLOZIN; CHROMANS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; GLYBURIDE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METFORMIN; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; SULFOTRANSFERASES; THIAZOLIDINEDIONES;

EID: 84978060372     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.070623     Document Type: Article

References (46)

1. Aleixandre de Artiñano A and Miguel Castro M (2009) Experimental rat models to study the metabolic syndrome. Br J Nutr 102:1246-1253.
2. Baldwin SJ, Clarke SE, and Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424-432.
3. Benedek IH, Blouin RA, and McNamara PJ (1985) Altered drug-serum protein binding in the genetically obese Zucker rat. J Pharm Sci 74:837-840.
4. Bhattia SK, Hadden DR, Montgomery DA, and Weaver JA (1970) Glibenclamide therapy in diabetes mellitus. BMJ 2:570-572.
5. Brouwer KLR, Kostenbauder HB, McNamara PJ, and Blouin RA (1984) Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther 231:649-653.
6. Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, and Blouin RA (1993) Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J Pharmacol Exp Ther 265:1333-1338.
7. Clark JB, Palmer CJ, and Shaw WN (1983) The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173:68-75.
8. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28:772-780.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
10. Donato MT, Gómez-Lechón MJ, Jover R, Nakamura T, and Castell JV (1998) Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284:760-767.
11. Donato MT, Guillén MI, Jover R, Castell JV, and Gómez-Lechón MJ (1997) Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J Pharmacol Exp Ther 281:484-490.
12. Dostalek M, Court MH, Hazarika S, and Akhlaghi F (2011a) Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 39:448-455.
13. Dostalek M, Court MH, Yan B, and Akhlaghi F (2011b) Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163: 937-947.
14. Enriquez A, Leclercq I, Farrell GC, and Robertson G (1999) Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 255:300-306.
15. Francke S, Mamidi RN, Solanki B, Scheers E, Jadwin A, Favis R, and Devineni D (2015) In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55:1061-1072.
16. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, and Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558.
17. Giroux M-C, Santamaria R, Hélie P, Burns P, Beaudry F, and Vachon P (2016) Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesia. Exp Anim 65:63-75.
18. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, and Kirkpatrick CM, et al. (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98.
19. Guengerich FP (1997) Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161-182.
20. He K, Woolf TF, Kindt EK, Fielder AE, and Talaat RE (2001) Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem Pharmacol 62:191-198.
21. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949.
22. Kava R, Greenwood MRC, and Johnson PR (1990) New rat models of obesity and type II diabetes: Zucker (fa/fa) Rat. ILAR J 32:4-88.
23. Kim MS, Wang S, Shen Z, Kochansky CJ, Strauss JR, Franklin RB, and Vincent SH (2004) Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 32:909-914.
24. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
25. Litterst CL (1980) In vitro hepatic drug metabolism and microsomal enzyme induction in genetically obese rats. Biochem Pharmacol 29:289-296.
26. Loi CM, Young M, Randinitis E, Vassos A, and Koup JR (1999) Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104.
27. Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, and Kelley MF, et al. (2014) Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos 42:903-916.
28. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
29. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
30. Ning M, Li L, Li J, Li Z, Li R, Zhou T, and Lu W (2012) In vitro screening of reversible and time-dependent inhibition on CYP3A by TM208 and TM209 in rat liver microsomes. Acta Pharm Sin B 2:181-187.
31. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, and Nakayama K, et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360.
32. Peterson RG, Shaw WN, Neel MA, Little LA, and Eichberg J (1990) Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR J 32:16-19.
33. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, and Hess JF (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18-19.
34. Qian L, Zolfaghari R, and Ross AC (2010) Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver. J Lipid Res 51: 1781-1792.
35. Raza H, John A, and Howarth FC (2015) Increased oxidative stress and mitochondrial dysfunction in zucker diabetic rat liver and brain. Cell Physiol Biochem 35:1241-1251.
36. Shiota M and Printz RL (2012) Diabetes in Zucker diabetic fatty rat. Methods Mol Biol 933: 103-123.
37. Shiratani H, Katoh M, Nakajima M, and Yokoi T (2008) Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
38. Sterne J (1959) [Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)]. Therapie 14:625-630.
39. Sunman JA, Hawke RL, LeCluyse EL, and Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359-363.
40. Truett GE, Bahary N, Friedman JM, and Leibel RL (1991) Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db). Proc Natl Acad Sci USA 88:7806-7809.
41. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
42. van den Berg SJ, Klaus V, Alhusainy W, and Rietjens IM (2013) Matrix-derived combination effect and risk assessment for estragole from basil-containing plant food supplements (PFS). Food Chem Toxicol 62:32-40.
43. Wang Z, Hall SD, Maya JF, Li L, Asghar A, and Gorski JC (2003) Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85.
44. Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, and Chaudhary AK (2011) Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci 100:2498-2507.
45. Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, and Ahmed MS (2009) Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol 78:1483-1490.
46. Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, Unadkat JD, Hebert MF, and Mao Q (2010) Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 31:228-242.